{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:24:01Z","timestamp":1740147841534,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with rheumatological diseases are at high risk of developing irreversible fibrotic changes, both articular and extra-articular, as a result of tissue damage caused by the chronic phase of persistent inflammation. Thus, our purpose was to study early markers of fibrosis formation in children with juvenile idiopathic arthritis (JIA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seventy patients with juvenile idiopathic arthritis, namely, polyarthritis (64.29%) and oligoarthritis (35.71%) variant JIA (mean age 13.3\u00a0years, 64.29% girls, 35.71% boys), were included in this 4-year prospective study. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels were determined by ELISA kits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We evaluated bFGF (mean: 7478.21\u00a0pg\/ml; min: 4171.56\u00a0pg\/ml; max: 18,011.25\u00a0pg\/ml) and VEGF (mean: 342.47\u00a0pg\/ml; min: 23.68\u00a0pg\/ml; max: 2158.91\u00a0pg\/ml) levels in children with JIA. Children with JIA had a higher VEGF level when JIA onset occurred after 15\u00a0years of age and they had a high disease activity; additionally, a higher bFGF level was observed in children older than 14\u00a0years and in those with a JIA onset after 15\u00a0years of age, the oligoarticular variant, a moderate disease activity and regardless of MTX administration but more often when MTX was administered at a dosage from 10 to 12.5\u00a0mg\/m<jats:sup>2<\/jats:sup>\/week.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Laboratory screening of fibrosis formation predictors could help identify patients who may be at greater risk of adverse outcomes. Children with JIA had higher bFGF and VEGF levels when JIA onset occurred after 15\u00a0years of age, depending on disease activity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00937-1","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T11:02:24Z","timestamp":1704193344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of fibrogenesis in children with JIA: a single-center pilot study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-4827","authenticated-orcid":false,"given":"Olga","family":"Pavlova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Shevchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Pavlov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetiana","family":"Holovko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liudmyla","family":"Bogmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"937_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-4939-8549-4_5","volume":"2018","author":"DR Germolec","year":"1803","unstructured":"Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers of inflammation. Methods Mol Biol. 1803;2018:57\u201379. https:\/\/doi.org\/10.1007\/978-1-4939-8549-4_5.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"937_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/imr.12971","volume":"302","author":"R Schuster","year":"2021","unstructured":"Schuster R, Rockel JS, Kapoor M, Hinz B. The inflammatory speech of fibroblasts. Immunol Rev. 2021;302(1):126\u201346. https:\/\/doi.org\/10.1111\/imr.12971.","journal-title":"Immunol Rev"},{"issue":"160","key":"937_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0011-2021","volume":"30","author":"S Kadura","year":"2021","unstructured":"Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30(160): 210011. https:\/\/doi.org\/10.1183\/16000617.0011-2021.","journal-title":"Eur Respir Rev"},{"issue":"12","key":"937_CR4","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3390\/diagnostics11122290.","volume":"11","author":"E Malczuk","year":"2021","unstructured":"Malczuk E, T\u0142ustochowicz W, Kramarz E, Kisiel B, Marczak M, T\u0142ustochowicz M, Ma\u0142ek \u0141A. Early myocardial changes in patients with rheumatoid arthritis without known cardiovascular diseases-a comprehensive cardiac magnetic resonance study. Diagnostics (Basel). 2021;11(12):2290. https:\/\/doi.org\/10.3390\/diagnostics11122290.","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"937_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/1573397116666200319155247","volume":"16","author":"G Hilal","year":"2020","unstructured":"Hilal G, Akasbi N, Boudouaya H, Salma K, Harzy T. Liver fibrosis in rheumatoid arthritis patients treated with methotrexate. Curr Rheumatol Rev. 2020;16(4):293\u20137. https:\/\/doi.org\/10.2174\/1573397116666200319155247.","journal-title":"Curr Rheumatol Rev"},{"issue":"8","key":"937_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.stem.2022.07.006.","volume":"29","author":"HE Talbott","year":"2022","unstructured":"Talbott HE, Mascharak S, Griffin M, Wan DC, Longaker MT. Wound healing, fibroblast heterogeneity, and fibrosis. Cell Stem Cell. 2022;29(8):1161\u201380. https:\/\/doi.org\/10.1016\/j.stem.2022.07.006.","journal-title":"Cell Stem Cell"},{"key":"937_CR7","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.2147\/IJN.S168998","volume":"13","author":"X Zhang","year":"2018","unstructured":"Zhang X, Kang X, Jin L, Bai J, Liu W, Wang Z. Stimulation of wound healing using bioinspired hydrogels with basic fibroblast growth factor (bFGF). Int J Nanomedicine. 2018;13:3897\u2013906. https:\/\/doi.org\/10.2147\/IJN.S168998.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"937_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, Ni Z, Zhang B, Zhang D, Luo F, Chen H, Sun X, Feng JQ, Qi H, Chen L. FGF\/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5(1):181. https:\/\/doi.org\/10.1038\/s41392-020-00222-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"937_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3748\/wjg.v26.i3.279","volume":"26","author":"M Ocker","year":"2020","unstructured":"Ocker M. Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. World J Gastroenterol. 2020;26(3):279\u201390. https:\/\/doi.org\/10.3748\/wjg.v26.i3.279.","journal-title":"World J Gastroenterol"},{"issue":"221","key":"937_CR10","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","volume":"30","author":"S Vimalraj","year":"2022","unstructured":"Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. Int J Biol Macromol. 2022;30(221):1428\u201338. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.129.","journal-title":"Int J Biol Macromol"},{"key":"937_CR11","doi-asserted-by":"publisher","unstructured":"Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif. 2021;54(4):e13009. https:\/\/doi.org\/10.1111\/cpr.13009.","DOI":"10.1111\/cpr.13009"},{"key":"937_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.rmed.2019.08.003","volume":"156","author":"AP Laddha","year":"2019","unstructured":"Laddha AP, Kulkarni YA. VEGF and FGF-2: promising targets for the treatment of respiratory disorders. Respir Med. 2019;156:33\u201346. https:\/\/doi.org\/10.1016\/j.rmed.2019.08.003.","journal-title":"Respir Med"},{"key":"937_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674343","volume":"12","author":"H Zhan","year":"2021","unstructured":"Zhan H, Li H, Liu C, Cheng L, Yan S, Li Y. Association of circulating vascular endothelial growth factor levels with autoimmune diseases: a systematic review and meta-analysis. Front Immunol. 2021;12: 674343. https:\/\/doi.org\/10.3389\/fimmu.2021.674343.","journal-title":"Front Immunol"},{"issue":"1","key":"937_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/16078454.2020.1766865","volume":"25","author":"MZ Song","year":"2020","unstructured":"Song MZ, Mao YM, Wu J, Pan HF, Ye QL. Increased circulating basic fibroblast growth factor levels in acute myeloid leukemia: a meta-analysis. Hematology. 2020;25(1):186\u201393. https:\/\/doi.org\/10.1080\/16078454.2020.1766865.","journal-title":"Hematology"},{"issue":"1","key":"937_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147374.","volume":"11","author":"M Hu","year":"2016","unstructured":"Hu M, Hu Y, He J, Li B. Prognostic value of Basic Fibroblast Growth Factor (bFGF) in lung cancer: a systematic review with meta-analysis. PLoS One. 2016;11(1): e0147374. https:\/\/doi.org\/10.1371\/journal.pone.0147374.","journal-title":"PLoS One"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00937-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00937-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00937-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T11:04:35Z","timestamp":1704193475000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00937-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00937-1","relation":{},"ISSN":["1546-0096"],"issn-type":[{"type":"electronic","value":"1546-0096"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Kharkiv Medical Academy of Postgraduate Education (Protocol of the Ethics Commission No. 1 dated 11.02.2021) in accordance with the ethical principles of medical research conducted on humans. The work was carried out in accordance with the requirements of the European Convention (Strasbourg, March 18, 1986), the Directive of the Council of the European Economic Community (Strasbourg, November 24, 1986), the Law of Ukraine (2002), \"The Procedure for Conducting Clinical Trials of Medicines and Examination of Clinical Materials trials\" and \"Standard regulations on ethics commission\" and was approved by the orders of the Ministry of Health of Ukraine No. 523 dated 07.12.2012 and No. 616 dated 08.03.2012. The study was carried out with minimal psychological losses on the part of the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}